GlycoMimetics Inc. (Nasdaq: GLYC) reported upbeat updated data from the Phase 1/2 trial for GMI-1271 to treat relapsed/refractory acute myeloid leukemia. The stock price soared $2.13 to close at $16.45.
Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998. |
|||
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
||
|